Egfr
Entity.
- Evidence
- 215 documents · 63 separate publishers
- Standing
- A name from our starting list; its record is kept up to date automatically from coverage
- Time
- first seen 12 Mar 2026, last seen 1 Nov 2026
- Measured
- 3% of mentions say something specific about it; the rest only name it
- As of
- 3 Nov 2026
Where this comes from
- an unnamed outlet · 2026-11-01 · Typ-1-Diabetes: Finerenon senkt eGFR bei 242 Erwachsenen zunächst leicht (opens the source in a new tab)
- Frontiers Precision Oncology · 2026-10-27 · Case report and literature review: histologic transformation from EGFR-mutant lung adenocarcinoma to squamous cell carcinoma with newly detected SMAD4 and … (opens the source in a new tab)
- Endpoints News · 2026-10-26 · #ESMO26: SystImmune/BMS and Hengrui detail data in EGFR-mutant lung cancer (opens the source in a new tab)
- PR Newswire · 2026-10-25 · 2026 ESMO | Innovent Presented Phase 1 Study Data for IBI3001, a First-in-Class EGFR/B7H3 Bispecific ADC (opens the source in a new tab)
- AllSci News · 2026-10-22 · BlossomHill partners with Foundation Medicine to build CDx assay for EGFR C797S drug BH-30643 (opens the source in a new tab)
- J Cancer Res Clin Oncol · 2026-10-20 · Combination of oral fluoropyrimidines and EGFR-directed antibodies in frail patients with metastatic colorectal cancer: a systematic review. (opens the source in a new tab)
- bioRxiv Cancer Biology · 2026-10-20 · A First-in-Class LZK Inhibitor Suppresses Tumor Growth and Potentiates EGFR and PI3K Pathway Blockade in Head and Neck and Esophageal Cancers (opens the source in a new tab)
- Neoplasma · 2026-10-14 · ctDNA retesting to guide anti-EGFR therapy in later-line metastatic colorectal cancer. (opens the source in a new tab)
- European Medical Journal · 2026-10-09 · Multidisciplinary Perspectives on the Evolving Management of EGFR-Mutated Metastatic NSCLC (opens the source in a new tab)
- AllSci News · 2026-10-07 · ArriVent's firmonertinib falls short in global Phase III EGFR exon 20 trial (opens the source in a new tab)
- Oncologist · 2026-10-03 · REVERCE II: A Phase II trial of regorafenib followed by anti-EGFR therapy versus reverse sequencing in refractory metastatic colorectal cancer. (opens the source in a new tab)